Auteurs:
Simoneau, Anne R, Gerner, Eugene W, Nagle, Ray, Ziogas, Argyrios, Fujikawa-Brooks, Sharon, Yerushalmi, Hagit, Ahlering, Thomas E, Lieberman, Ronald, McLaren, Christine E, Anton-Culver, Hoda, Meyskens, Frank L, Jr
Source:
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 17(2)
Mots-clés sujets:
Adult, Aged, Antineoplastic Agents: pharmacology, Biopsy, Eflornithine: pharmacology, Genotype, Humans, Male, Middle Aged, Polyamines: metabolism, Polymorphism, Genetic, Prostate: drug effects, pathology, Prostate-Specific Antigen: blood, Prostatic Neoplasms: genetics, metabolism, pathology, prevention & control, Statistics, Nonparametric, Tumor Markers, Biological: blood, biological marker, eflornithine, ornithine decarboxylase, placebo, polyamine, prostate specific antigen, putrescine, adult, aged, article, audiography, cancer growth, cancer size, chemoprophylaxis, clinical trial, controlled clinical trial, controlled study, double blind procedure, drug mechanism, erectile dysfunction, gastrointestinal symptom, genotype, hearing, human, human tissue, hyperplasia, intervertebral disk disease, major clinical study, male, men's health, musculoskeletal disease, ototoxicity, phase 2 clinical trial, priority journal, prostate cancer, randomized controlled trial, sexual dysfunction, side effect, tendinitis, tinnitus, tumor biopsy, unspecified side effect, vertigo, Adult, Aged, Antineoplastic Agents, Biopsy, Eflornithine, Genotype, Humans, Male, Middle Aged, Polyamines, Polymorphism, Genetic, Prostate, Prostate-Specific Antigen, Prostatic Neoplasms, Statistics, Nonparametric, Tumor Markers, Biological
Description du fichier:
application/pdf